

# CUBAN BIOTECH AND PHARMACEUTICAL INDUSTRY: RESULTS AND PERSPECTIVES

# GROUP OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES

MsC. Yodira Pérez Díaz Business Executive







**CNIC** 



I. FINLAY



**Farmacuba** 



#### **32 Enterprises**

### 78 manufacturing facilities



- 6325 Higher education (Universities).
- 262 PhD.
- 1170 MSc.
- 719 Researchers









LIORAD





**BioCen** 









Lab. Roberto Escudero

# **Cuban Biotech impact on Cuban Health**






VOLUME 22 SUPPLEMENT DECEMBER 2004 NATURE BIOTECHNOLOGY

#### 3.12 - Evolución de la estructura por edades de la población de Cuba Evolution of the age structure of the Cuban population

				Por ciento
AÑOS	Total	0 - 14	15 - 59	60 y más
1907 <sup>(a)</sup>	100,0	36,6	58,8	4,6
1919 <sup>(a)</sup>	100,0	42,3	52,9	4,8
1931 <sup>(a)</sup>	100,0	37,4	57,5	5,1
1943 <sup>(a)</sup>	100,0	35,5	58,9	5,6
1953 <sup>(a)</sup>	100,0	36,2	56,9	6,9
1970 <sup>(a)</sup>	100,0	36,9	54,0	9,1
1981 <sup>(a)</sup>	100,0	30,3	58,8	10,9
2002 <sup>(a)</sup>	100,0	20,5	64,8	14,7
2005 <sup>(b)</sup>	100,0	19,0	65,3	15,7
2010 <sup>(b)</sup>	100,0	17,3	64,9	17,8
2014 <sup>(b)</sup>	100,0	16,7	64,3	19,0
2015 <sup>(b)</sup>	100,0	16,5	64,1	19,4
Proyecciones				
2020	100,0	16,4	62,1	21,5
2025	100,0	16,4	57,7	25,9
2030	100,0	15,5	54,4	30,1

<sup>(</sup>a) Censo de Población y Viviendas. (b) Sistema de Información Estadística.



DOM: SOURCES — INCOME World Starks GDP per capits, PPP (consum 2011 international S), as often Hz (2015, with in the world stark and log-scale to three doubling of incomes as some discusses on all wells. — LPE LEFE CONNECT (PMS 2014 Available from http://whitchbestelder./



#### **BIOCUBAFARMA**

1099 Products are manufactured and supplied to Cuban Health System

Source of more than 65% of Cuban Basic Drug Table

Vaccines: Prophylactics and therapeutics

(biosimilars and innovatives)

Monoclonal antibodies and other recombinant proteins for autoinmmune diseases.

(biosimilars and innovatives)

**Veterinary products** 

**Agricultural products** 

**Pharmaceutical products (Generics)** 

Laboratory equipments and diagnostic kits for the early diagnosis and follow up of different diseases and programs

Medical devices and softwares of high technology for diagnostic and treatment of neurological desorders and for diagnosis and monitoring cardiovasculars deseases

**Natural origin products** 

**Comprehensive Health Care Programs** 

### **COMMERCIAL PIPELINE**











#### <u> 1981 – 1990</u>

- Meningitis bc vaccine IFN alfa 2b
- Diagnostics

#### 1991 - 2000

- Meningitis BC vaccine
- · Hepatitis B vaccine
- Heberkinasa
- IFN alfa 2b
- Hebermin
- Gavac
- SUMA System
- DIRAMIC
- Hebertrans
- · Culture media
- PPG
- Trofin
- Natural products
- · Neurodiagnostic systems
- Anti-CD3 monoclonal antibody
- Surfacen
- Generics
- Placenta derivatives
- Neurological restoration services

#### <u>2001 – 2015</u>

- Meningitis BC vaccine
- Hepatitis B vaccine
- Hib vaccine
- DTP Vaccine
- dT vaccine
- Tetanus vaccine
- Tetravalent DPT-HB vaccine,
  - Pentavalent DPT-HB-Hib Vaccine
- Meningitis ACYW135 vaccine
- Leptospirae vaccine
- Typhoid fever vaccine
- Heberprot-P
- Humanized anti EGF-receptor antibody (h-R3)
- Therapeutic base-EGF cancer vaccine
- EPO
- G-CSF
- Hebermin
- Products and equipment for Neurophysioloy and Neuroinformatics
- Several diagnostic systems
- SUMA system
- Heberkinasa (Streptokinase)
- IFN alfa 2b
- IFN gamma
- Allergens
- Trofin
- Interferon + ribavirine
- PPG
- Agriculture products (GAVAC, Bionematicide)
- Acuabio 1
- Hebertrans
- Culture media
- New advanced generics
- Cytostatics
- Placenta derivatives
- Surfacen
- Generic Medicine



#### **OVERVIEW OF BIOCUBAFARMA ABROAD**

- ☐ 167 invencions / 2438 granted patents
  - Biotecnology: 2337
  - Pharmaceutical: 35,
  - Diagnostics and Medical equipments: 66
- □ More than thousands publications in impact scientific journals
   □ Exporting products to more than 50 countries
   □ 893 marketing approvals abroad
   □ More than 30 Clinical Trials in 18 countries
   □ Experience in more than 9 suscesfull technology transfers (South South Cooperation basis)
   □ 5 Joint Venture Companies abroad
   □ More than 70 long term established partnership for Biopharmaceuticals, worldwide




### WHAT DOES BIOCUBAFARMA OFFERS?

# Biological Products (28 marketing approvals)

### 91 Products / Health targeted projects

- → 33 Products against infectious diseases.
- ► 33 Oncologic products
- > 18 Cardiovascular products
- > 7 Diabetes and other pathologies





#### WHAT DOES BIOCUBAFARMA OFFERS?

☐Innovative capacity: + 100 R&D projects (Biomedics, agriculture)
☐ High technology manufacturing capacities for pharmaceuticals
☐International recognition in medicine and biotechnology
□Validated comprehensive health programs to achieve high social impact
□Potentialities of industry growth with access to big markets as part of opening of relationship with US

Blog | October 17, 2016

Will Cuba Be The World's Next Leading Biotech Hub?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL

Cuba's cancer initiatives were sufficiently eye opening to prompt Roswell Park to secure a license from the U.S. Office of Foreign Assets Control (OFAC) to partner with CIM toward the development of the country's therapeutic lung cancer vaccine (i.e.,, CIMAvax).




# **PERSPECTIVES**

- ☐ To increase impact of biopharmaceuticals in health in Cuba
- To extend long terms partnership for the manufacturing, development and commercialization of our products in significant markets
- ☐ To start and consolidate investment process in Special Zone of Development in Mariel to build new facilities for monoclonal antibodies, vaccines, pharmaceuticals.
- ☐ To introduce innovative products into the most regulated markets such us US, Europe and Japan



## PARTNERING OBJECTIVES



- Co-development capacity for early stage biopharma projects and sharing commercial opportunities with players.
- To access to clinical trial capacities for late stage development products
- Investment in Cuba and abroad creating capacities to access international markets
- Impact in health care with our programs abroad Cuba implementing our Comprehensive Health care programs





**CIMAB**<sub>5A</sub>











Vaccines, pharmaceuticals, diagnostics, plant and animal biotechnology. www.cigb.edu.cu; www.heber-biotec.com

Monoclonal antibodies, Therapeutic Cancer Vaccines and other biotech products for autoinmmune diseases. www.cim.cu; www.cimab-sa.com

Products from natural origin (sugar cane, bee wax, etc.) www.cnic.edu.cu; www.dalmer.cnic.edu.cu



SUMA® Technology: Laboratory equipments and diagnostic kits for the early diagnosis and follow up of different diseases and programs. www.tecnosuma.com

Vaccines against infectious deseases. www.finlay .sld.cu

Medical devices and softwares of high technology for diagnostic and treatment of neurological desorders.

www.neuronicsa.com

Medical devices for diagnostic and monitoring of cardiovascular deseases. www.combiomed.sld.cu

Pharmaceutical products www.farmacuba.cu

Thank you very much!!